Prostate-specific antigen (PSA) response with darolutamide in metastatic hormone-sensitive prostate cancer and its impact on treatment outcomes in the ARASENS trial: a plain language summary

Saad, Fred; Hussain, Maha H.A.; Tombal, Bertrand; Fizazi, Karim; Mastris, Ken; Flannery, Thomas; Smith, Matthew R.

doi:10.1080/14796694.2025.2476929

Prostate-specific antigen (PSA) response with darolutamide in metastatic hormone-sensitive prostate cancer and its impact on treatment outcomes in the ARASENS trial: a plain language summary

Saad, Fred

;

Hussain, Maha H.A.

;

Tombal, Bertrand

;

Fizazi, Karim

;

Smith, Matthew R.

;et.al.

(2025) Future Oncology — Vol. 21, n° 10, p. 1157-1170 (2025)

Files

Saad_Arasens40130700.pdf

Open Access
Adobe PDF
3.44 MB

Download

Details

Authors

Saad, Fred
Author
Hussain, Maha H.A.
Author
Tombal, BertrandUCLouvain
Author
Fizazi, Karim
Author
Smith, Matthew R.
Author

Affiliations

UCLouvainSSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation

Citations

APA
Chicago
FWB

Saad, F., Hussain, M. H. A., Tombal, B., Fizazi, K., Mastris, K., Flannery, T., & Smith, M. R. (2025). Prostate-specific antigen (PSA) response with darolutamide in metastatic hormone-sensitive prostate cancer and its impact on treatment outcomes in the ARASENS trial: a plain language summary. Future Oncology, 21(10), 1157-1170. https://doi.org/10.1080/14796694.2025.2476929 (Original work published 2025)